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Abstract
Apoptotic debris, autoantibody, and IgG-immune complexes (ICs) have long been implicated in 
the inflammation associated with systemic lupus erythematosus (SLE); however, it remains 
unclear whether they initiate immune-mediated events that promote disease. In this study, we show 
that peripheral blood mononuclear cells from SLE patients experiencing active disease, and 
hematopoietic cells from lupus-prone MRL/lpr and NZM2410 mice accumulate markedly elevated 
levels of surface-bound nuclear self-antigens. On dendritic cells (DCs) and macrophages (MFs), 
the self-antigens are part of IgG-ICs that promote FcγRI-mediated signal transduction. 
Accumulation of IgG-ICs is evident on ex vivo myeloid cells from MRL/lpr mice by 10 weeks of 
age, and steadily increases prior to lupus nephritis. IgG and FcγRI play a critical role in disease 
pathology. Passive transfer of pathogenic IgG into IgG-deficient MRL/lpr mice promotes the 
accumulation of IgG-ICs prior to significant B cell expansion, BAFF secretion, and lupus 
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nephritis. In contrast, diminishing the burden IgG-ICs in MRL/lpr mice through deficiency in 
FcγRI markedly improves these lupus pathologies. Together, our findings reveal a previously 
unappreciated role for the cell surface accumulation of IgG-ICs in human and murine lupus.
Introduction
Systemic lupus erythematosus (SLE) is a multi-systemic autoimmune disease with genetic 
and environmental components that lead to autoimmunity and tissue-damaging 
inflammation (1, 2). There has long been an association between elevated levels of apoptotic 
debris and immune complexes (ICs), and their decreased clearance in SLE (3). Defects in 
opsonins such as mannose binding protein, complement components, and C-reactive protein 
reduce the clearance of apoptotic debris (4), and deficiency in DNase or RNase leads to poor 
lysosomal degradation (5). Although these defects heighten the burden of apoptotic debris 
and promote some of the phenotypes associated with lupus, ablation of opsonins or their 
receptors is insufficient to promote severe disease (6, 7). One consequence of heightened 
apoptotic debris is the exposure of the immune system to normally privileged nuclear self-
antigens (8, 9). Cell-derived autoantigens exposed on apoptotic debris form immune 
complexes (ICs) when bound by autoreactive IgG (henceforth referred to as IgG-ICs). Upon 
binding FcγRs or B cell receptors (BCRs), they promote immune activation of B cells, 
macrophages (MFs) and dendritic cells (DCs) in part by delivering ligands to TLR7 and 
TLR9 (10, 11).
Activating FcγRs on human (FcγRI/IIa/IIc/IIIa) and murine (FcγRI/III/IV) phagocytic cells 
contain ITAM motifs that recruit Syk and activate the PI3k pathway (12). Activation of 
FcγRs (FcγRI, III, and IV in mouse) is regulated by co-ligation with ITIM-containing 
inhibitory (FcγRIIB) receptors. In mouse, FcγRIIB represses ITAM-containing FcγRs by 
recruiting SHIP to dephosphorylate PI(3,4,5)P3 thereby limiting downstream signal 
propagation (13, 14) and by SHP-1 through inhibitory signaling conditions called ITAMi 
that desensitizes receptor signal transduction (15).
Studies have identified FcγR polymorphisms as genetic factors influencing susceptibility to 
SLE and other autoimmune diseases (16, 17). Promoter polymorphisms that reduce FcγRIIB 
expression on germinal centers (GCs) and activated B cells are associated with murine and 
human SLE (18, 19). In addition, mice lacking FcγRIIB (20) develop lupus-like disease. 
Other functional polymorphisms in human FcγRIIa (R/H131) and FcγRIIIa (158V/F) 
decrease binding to IgG and are thought to diminish clearance of apoptotic debris, yet they 
are associated with lupus nephritis (21). Thus, polymorphisms in both activating and 
inhibitory FcγRs are associated with disease.
The pathogenic role of IgG-ICs in lupus has long been associated with their deposits in the 
kidneys and their ability to activate complement (C3) in lupus nephritis (22, 23). However, 
later studies showed that deposits of IgG and complement persist in the kidneys of lupus-
prone mice when proteinuria and morbidity were diminished by blockade or genetic ablation 
of BAFF (24, 25). This indicates that IgG and complement deposits are not sufficient to 
induce lupus nephritis. Further studies using bone marrow chimeras showed that expression 
of FcγR on hematopoietic cells, rather than kidney mesangial cells, is required for lupus 
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nephritis (26). This indicates that activation of the immune system through FcγRs on 
hematopoietic cells, rather than the deposits of IgG-IC in the kidney, is important in lupus 
nephritis. Studies also show that IgG-ICs promote autoantibody secretion in a TLR-
dependent manner, and they contribute to immune responses associated with SLE in a TLR-
independent manner (10, 11). However, it remains unclear how IgG-ICs plays a role in the 
pathogenic processes of SLE beyond internalizing TLR ligands to activate B cells.
In this manuscript we show that IgG and apoptotic antigens (as IgG-ICs) accumulate on the 
surface of myeloid cells prior to the onset of SLE. In lupus-prone mice, nuclear self-antigens 
were displayed on hematopoietic cells, and in SLE patients, 67–75% with active disease 
accumulated nuclear self-antigens on peripheral blood B and T cells, and 10–40% displayed 
nuclear self-antigens on monocytes. On murine DCs and MFs, the antigens were contained 
within IgG-ICs bound to the activating Fc receptors, FcγRI and FcγRIV. In MRL/lpr mice, 
accumulation of IgG-ICs on FcγRI induced activation of the PI3k pathway and preceded 
lupus nephritis, whereas MRL/lpr mice lacking FcγRI (FcγRI−/−MRL/lpr) were protected. In 
contrast, inducing the accumulation of IgG-IC on the cell surface by passive transfer of anti-
nucleosome IgG into AID−/−MRL/lpr mice promoted serological autoimmunity, BAFF 
secretion, and lupus nephritis. Together, these data identify that the accumulation of IgG-ICs 
on hematopoietic cells occurs during human and murine SLE and is associated with 
autoimmunity and disease pathogenesis.
Methods
Animals
C57B6 (B6) and MRL/MpJ-Tnfrs6lpr/J (MRL/lpr; JAX Stock # 000485) colonies were 
maintained in an accredited animal facility at University of North Carolina at Chapel Hill 
(UNC-CH). FcγRI−/− (27, 28) and FcγRIII−/− mice (29) were obtained from Dr. Anne 
Sperling, FcγRIIB−/− (30), FcγRIV−/− (31) from Dr. Charles Jennette, FcRγc−/− (32) from 
Dr. Alex Szalai. NZM2410 mice (33) were from Dr. Gary Gilkeson. MRL/MpJ mice were 
purchased from JAX (Stock # 000486). AID−/−MRL/lpr mice were obtained from Dr. 
Marilyn Diaz at NIEHS (34). FcγRI−/−C57B6 mice were crossed with MRL/lpr mice for 12 
generations, followed by an intercross of FcγRI+/−MRL/lpr for 2 generations to produce 
FcγRI−/−MRL/lpr mice. Tail DNAs were analyzed by PCR (27).
Human samples
Patients who showed SLEDAI scores ≥6, as defined by the Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI), were selected for enrollment after informed consent in 
accordance with the UNC institutional internal review board. Peripheral blood samples were 
collected with sodium heparin (BD Biosciences) during routine clinic visits.
Passive administration of anti-nucleosome antibody
AID−/−MRL/lpr, FcγRI−/−MRL/lpr, or B6 mice (18 to 21 weeks old) were injected with 500 
μg of PL2-3 (anti-nucleosome, IgG2a) (35), F(ab′)2 of PL2-3, or Hy1.2 (isotype control 
IgG2a, anti-TNP) intravenously (i.v.) per mouse every week for 2 or 5 weeks. Five days after 
the 5th injection, mice were euthanized.
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Splenocytes or total kidney cells were prepared into a single cell suspension. Splenic DCs 
and MFs were isolated using MicroBeads for CD11c+ cells (DCs) and CD11b+ cells (MFs) 
following the manufacturer’s instructions (Miltenyi Biotec).
ELISA
For serum anti-nucleosome and anti-dsDNA IgM or IgG levels, plates were coated with 
dsDNA (10 μg/ml, Sigma) in the presence or absence of histone (40 μg/ml, Sigma). Total 
serum IgM or IgG levels were measured on a plate coated with anti-IgM or anti-IgG 
antibodies. For serum BAFF, anti-mouse BAFF (5A8, Enzo) and biotinylated anti-mouse 
BAFF (1C9, Enzo) were used. Duplicates of serially diluted serum samples were tested.
ELISpot
To analyze the numbers of BAFF secreting cells, isolated splenic DCs or MFs (1x106 and 
0.5x106 cells per well) were incubated for 60 hours at 37°C on a ELISpot plates (Millipore) 
coated with 5A8, then detected using biotinylated 1C9.
Histology
Formalin fixed (10%), paraffin-embedded kidneys were stained with H&E (8 micron 
sections). Glomerular changes and tubulointerstitial inflammation were assessed by a 
pathologist blinded to the experimental groups. The following criteria were used; 
Glomerular lesions: (0) no H&E changes, (1) minimal mesangial hypercellularity without 
visualized immune deposits, (2) focal immune deposits, (3) diffuse glomerulonephritis with 
widespread subendothelial immune deposits, (4) global immune deposits with associated 
sclerosis. Interstitial inflammation was scored 0–3 based on the degree of tubulointerstitial 
involvement: (0) no infiltrate or inflammation, (1) less than 10%, (2) between 10% and 50%, 
(3) >50% of the tubulointerstitium.
Proteinuria scoring
Urine protein was measured using Uristix strip following the manufacturers instruction 
(Siemens).
Immunofluorescence
Snap-frozen kidney sections (8 micron) were stained with goat anti-mouse IgG-Fc 
conjugated with DyLight 488 (Jackson Immunoresearch), and PE-conjugated anti-mouse 
complement component 3 (C3) (Cedarlane), and then visualized on LSM 710 confocal 
microscope (20x magnification lens, Carl Zeiss).
Flow Cytometry
Total splenocytes were stained with biotinylated 2.12.3 (mouse anti-mouse Sm, IgG2a) (36, 
37), or goat anti-mouse IgG-Fc (Jackson Immunoresearch). Biotinylated anti-canine 
distemper virus (CDV, IgG2a), or goat anti-rabbit IgG were used as isotype control staining 
antibodies (ISO). Biotinylated antibodies were detected using streptavidin-Alexa Fluor 647 
(Invitrogen). The mean fluorescent intensity (MFI) of surface bound antigen or IgG staining 
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was divided by the MFI values of ISO. For intracellular staining, fixed and permeabilized 
cells were stained with anti-mouse total Syk (Santa Cruz), pSyk (BD Biosciences), total Akt, 
pAkt-Threonine (Thr 308), total S6, or pS6 (Cell Signaling). The expression levels of 
intracellular kinases were calculated as follows; (MFI of phosphorylated signaling 
molecule/MFI of ISO)/(MFI of total signaling molecule/MFI of ISO). The fold changes over 
average values of control mice from each group are graphed. For FcγRI staining, cells were 
blocked with rat serum and stained with biotinylated X54-5/7.1. Whole blood cells from 
healthy donors or SLE patients were stained for surface DNA (anti-human DNA, 33H11, T. 
Winkler; University of Erlangen, Germany) (38), Sm (2.12.3), or IgG (anti-human IgG Fc-
PE, Jackson Immunoresearch). 33H11 and 2.12.3 were conjugated to Alexa Fluor 647 
following manufacturer’s instruction (Invitrogen). Samples were acquired on Cyan flow 
cytometer (Beckman). Cells were defined as follows; human and mouse B cells (CD19+) 
and T cell (CD3+), mouse DCs (CD11chiCD11b+), mouse MFs (CD11c−CD11bhi), and 
human monocytes (CD14+). Murine non-leukocytes are gated as CD45neg population.
Microscopy
Isolated murine splenic DCs or MFs, or whole blood cells from human samples, were 
stained for IgG, Sm (2.12.3) or DNA (33H11). Colocalization was quantified by calculating 
the Mander’s coefficient using Image J. For some experiments, cells were incubated with 
trypsin or DNase for 20 min (37°C) prior to the staining for surface bound antigens.
Real time PCR
Splenic MFs were isolated by incubation on a glass dishes for 2 hours at 37°C. RNA was 
extracted using RNeasy Mini Kit (Qiagen). cDNA was generated using iScript cDNA 
synthesis kit (BioRad). The following PCR primers were used: GAPDH, forward 5′-GGC-
AAA-TTC-AAC-GGC-ACA-3′ and reverse 5′-GTT-AGT-GGG-GTC-TCG-CTC-CTG-3′; 
for FcγRI, forward 5′-ACA-CAA-TGG-TTT-ATC-AAC-GGA-ACA-3′ and reverse 5′-TGG-
CCT-CTG-GGA-TGC-TAT-AAC-T-3′. Quantitative real-time PCR was performed on ABI 
Prism 7500 Sequence Detection System (Applied Biosystems).
Statistics
The Mann-Whitney test was used to analyze human data. Kruskal-Wallis test (>3 groups) or 
Mann-Whitney test (≤3 groups) was used to compare changes over control group. One-way 
ANOVA was used to compare changes between different conditions. Statistical analysis was 
performed using GraphPad Prism (GraphPad Software, Inc.).
Results
Nuclear self-antigens are displayed on hematopoietic cells
The clearance of apoptotic debris is critical in maintaining immune homeostasis; however in 
autoimmune-prone mice, continuous cell turnover can expose the immune system to self-
antigens on apoptotic debris. To assess whether apoptotic debris was present on cells from 
non-autoimmune C57BL/6 (B6) mice, we stained splenocytes with antibodies specific for 
Smith (Sm), a nuclear self-antigen evident on apoptotic debris (9). Although Sm was not 
detected on B6 T cells, the levels of Sm were heightened 7–10 fold on splenic DCs, MFs, 
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and B cells when compared to isotype control antibody (Figure 1A). Staining was not unique 
to anti-Sm as antibodies specific for DNA (33H11), and nucleosomes (PL2-3) showed a 
similar staining pattern (Supplemental Figure 1A), that by microscopy appeared punctate 
(Figure 1B). To further characterize the antigens, we treated B6 splenocytes with trypsin 
(Figure 1B) or DNase (Figure 1C), prior to surface staining for DNA, nucleosome, or Sm. 
DNase treatment specifically removed DNA, while nucleosomes remained intact. As 
expected, all nuclear self-antigens were removed by trypsin in agreement with their display 
on the cell surface. These data indicate that nuclear self-antigens contained within apoptotic 
debris are displayed on the surface of hematopoietic cells.
Elevated levels of apoptotic debris have been associated with autoimmunity in murine and 
human SLE (39). To assess whether hematopoietic cells displayed elevated levels of nuclear 
self-antigens, we quantified the levels of Sm on cells from MRL/lpr mice aged 18–26 weeks 
(Figure 1D and 1F). Relative to isotype control, Sm levels increased 84- to 260-fold on DCs, 
MFs and B cells. Surprisingly, T cells also displayed a 109-fold increase. The staining was 
specific, as T cells from B6 mice did not display Sm (Figure 1A). Further, Sm was not 
evident on splenic non-leukocyte populations (CD45neg) from B6 or MRL/lpr mice (Figure 
1D), indicating that the accumulation of nuclear self-antigens is restricted to hematopoietic 
cells. No differences between genders were observed. To further assess whether nuclear self-
antigens on splenic hematopoietic cells and peripheral blood mononuclear cells from B6 and 
MRL/lpr mice accumulated over time, we quantitated the levels of Sm over 30 weeks 
(Figure 1E). Surprisingly, by 3 weeks of age, DCs, monocytes/MFs, B cells, and T cells 
from blood and spleen of MRL/lpr mice showed high levels in surface Sm (10-, 3-, 5-, and 
30-fold on DCs, MFs, B cells, and T cells), compared to peripheral blood cells or 
splenocytes from B6 mice (single data points at weeks 3, 6, and 30). These levels declined 
during the next 6 weeks. After week 9, the levels of Sm on splenic MFs and B cells steadily 
increased, reaching a maximal level at 30 weeks when urine protein levels are high (score 
>2) (Supplemental Figure 1B). Similarly, the Sm levels on blood and splenic DCs and T 
cells, and blood monocytes showed steady increase after 9 weeks, returning to levels found 
at week 3.
To assess whether accumulation of nuclear self-antigens was unique to the MRL/lpr 
background, we examined other models. In NZM2410 mice, Sm levels were heightened on 
the surface of all hematopoietic cells, reaching levels that were 35–78 fold higher than 
isotype control (Figure 1F). Similarly, Sm levels were elevated on cells from MRL/MpJ 
mice, but not on cells from B6/lpr or B6/Merkd (Figure 1F), suggesting that accumulation of 
nuclear self-antigens is associated with the lupus-prone background.
SLE patients with active disease exhibit heightened levels of surface bound nuclear 
antigens
The accumulation of nuclear self-antigens in two spontaneous models of murine SLE 
suggests an inherent defect in immune cells that could be present in human SLE. To assess 
this, we analyzed circulating mononuclear cells from healthy controls and SLE patients for 
surface Sm and DNA (Figure 2). We chose SLE patients experiencing active disease 
(SLEDAI > 6), since active disease in humans might be most like disease in MRL/lpr mice 
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(Supplemental Table 1). Similar to non-autoimmune mice (Figure 1A), healthy controls 
showed low levels of Sm and DNA on B cells and monocyte, but not T cells (Figure 2A, B). 
In contrast, 67–75% of SLE patients showed more than a 2-fold increase of Sm and DNA on 
B and T cells compared to healthy controls. Among the patients with active disease, there 
was significant variation in the levels of Sm and DNA on the B cells. In the case of DNA, 
two SLE patients showed 30- to 40-fold increases, four showed 2- to 7-fold increases, and 
the rest showed less than a 2-fold increase. On blood monocytes, 10–40% of SLE patients 
showed a 2- to 3-fold increase of Sm and DNA (Figure 2A). The findings that blood 
monocytes from SLE patients accumulate less nuclear self-antigens compared to healthy 
controls is consistent with the murine data where blood monocytes showed similar levels of 
surface Sm as B6 blood monocytes (Figure 1E). In the patients whose monocytes, B and T 
cells showed an accumulation of nuclear self-antigens (Figure 2A), microscopy showed 
punctate staining of DNA (Figure 2C; T cell example) similar to that seen in lupus-prone 
mice, suggesting receptor aggregation. Thus, the data show that nuclear self-antigens 
accumulate on hematopoietic cells in human and murine lupus.
Nuclear self-antigens are bound to FcγRs as IgG-immune complexes
Multiple cell surface receptors clear apoptotic debris, including FcγRs. One possibility is 
that the nuclear self-antigens displayed on myeloid cells represent immune complexes (ICs) 
bound to FcγRs. To test this idea, we quantified the levels of Sm on immune cells from B6 
mice that were deficient in individual FcγRs (Figure 3A). We found that loss of activating 
receptor FcγRI or FcγRIV reduced Sm levels 40% or 45% on B6 DCs, and 50% on B6 MFs. 
The receptor(s) displaying self-antigen on B and T cells remains unclear; however, 
consistent with the limited expression of FcγRs on B and T cells, loss of any FcγR did not 
reduce the levels of Sm by more than 10% (data not shown).
We reasoned that if accumulated nuclear self-antigens were part of immune complexes (ICs) 
bound to FcγRI/FcγRIV, surface IgG levels would be elevated on myeloid cells. In B6 mice, 
DCs and MFs consistently showed low levels of IgG (Figure 3B) and Sm (Figure 1A, 1E) 
over 30 weeks, and they failed to develop lupus nephritis (Supplemental Figure 1B). In 
MRL/lpr mice, the levels of IgG remained low (at levels of B6 mice) until 10 weeks of age, 
then steadily increased until 20 weeks, rising sharply between weeks 20 and 30 (14-fold on 
DCs, 5-fold on MFs compared to B6). This was consistent with the changes in the levels of 
Sm between 10 to 30 weeks of age (Figure 1E). On DCs and MFs, 70% of the surface IgG 
was IgG2a and IgG2b (Supplemental Figure 1C) that appeared prior to high levels of 
proteinuria (score >2; Supplemental Figure 1B). In addition, SLE patients that accumulated 
Sm and DNA on blood monocytes also expressed surface IgG (Supplemental Figure 1D). 
Display of nuclear self-antigens on myeloid cells did not involve FcμR because IgM was not 
found on DCs or MFs from B6 or MRL/lpr mice (Supplemental Figure 1E).
To further define the role of ICs in the surface display of self-antigen, we assessed whether 
Sm and IgG colocalized and showed punctate staining. We found a 6-fold and 4-fold 
increase in the colocalization of Sm and IgG on MRL/lpr DCs and MFs that exhibited 
punctate staining consistent with receptor aggregation (Figure 3C–D). To assess whether cell 
signaling was occurring, we measured the activation state of kinases coupled to FcγRs. We 
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found that the levels of pSyk were increased 2–3 fold, pAkt-Thr308 1.4-fold, and pS6 2-fold 
in both MRL/lpr DCs and MFs, suggesting chronic activation of the PI3k pathway (Figure 
3E–G). Thus, myeloid cells from MRL/lpr mice accumulate IgG-ICs containing nuclear 
antigens that are bound in part by FcγRI and FcγRIV.
One possibility was that accumulation of IgG-ICs on MRL/lpr DCs and MFs might reflect 
increased expression of FcγR. We found that DCs and MFs from MRL/lpr mice showed 3-
fold and 2-fold increases in FcγRI compared to B6 mice (Figure 3H). Since the elevated 
levels of FcγRI could reflect an increased rate of transcription, we quantitated FcγR message 
levels by pPCR. Surprisingly, we found that the levels of FcγRI mRNA from MRL/lpr mice 
were comparable to those in B6 mice (Figure 3I). This indicates that accumulation of IgG-
ICs on the cell surface is associated with increased surface expression of FcγRI; however, 
these increased levels do not reflect increased transcription, suggesting that the FcγRs might 
be recycled.
FcγRI−/−MRL/lpr mice show reduced levels of IgG-ICs and diminished autoantibody levels
Our findings indicate that IgG-ICs accumulate on hematopoietic cells in human and murine 
SLE and induce signal transduction induced by activating FcγRs. To define whether FcγRI 
contributes to disease, we used MRL/lpr mice deficient in FcγRI (FcγRI−/−MRL/lpr). 
Previous studies have found that MRL/lpr mice have elevated splenic and lymph node 
cellularity due to enhanced lymphoproliferation (40). Loss of FcγRI in MRL/lpr mice 
reduced the numbers of splenic DCs and MFs to levels found in B6 mice, and partially 
reduced the numbers of T and B cells (Figure 4A). This suggests that FcγRI plays a 
significant role in the expansion of myeloid cells in MRL/lpr mice. Although B and T cells 
typically do not express FcγRI, their numbers were reduced in FcγRI−/−MRL/lpr mice, 
suggesting that loss of FcγRI may indirectly impact lymphocytes.
To define whether FcγRI contributes to the accumulation of ICs in vivo, we quantitated the 
levels of surface Sm and IgG on DCs and MFs from FcγRI−/−MRL/lpr mice. Compared to 
MRL/lpr mice, the levels of Sm were reduced 30–40% on DCs and MFs (Figure 4B), and 
the levels of IgG were decreased to levels found on B6 cells (Figure 4C). This reduction was 
similar to the contribution of FcγRI in the low level of IgG-ICs displayed on DCs and MFs 
from B6 mice (Figure 3A). The levels of Sm on B and T cells were not altered in the 
absence of FcγRI, consistent with the lack of FcγRI expression on these cells (Figure 4B) 
and the idea that other receptors are involved in the display of self-antigens on lymphocytes.
To establish whether the accumulation of IgG-ICs contributes to the autoimmune phenotype 
of MRL/lpr mice, we quantitated the levels of intracellular pSyk, pAkt, pS6, serum BAFF, 
and autoantibody levels in FcγRI−/−MRL/lpr mice. In these mice, the levels of pSyk and pS6 
in MFs and DCs, and the levels of pAkt-Thr308 in DCs were diminished to the levels found 
in B6 mice, while the levels of pAkt-Thr308 in MFs were only reduced 15% (Figure 4D–F). 
Further, FcγRI−/−MRL/lpr mice showed a 200-fold decrease in serum anti-nucleosome 
antibody (Figure 4G), and a 95-fold decrease in serum anti-dsDNA antibodies (Figure 4H) 
when compared to MRL/lpr (FcγRI+/+) mice. Similarly, FcγRI−/−MRL/lpr mice showed a 4-
fold decrease in serum BAFF (Figure 4I). Despite these significant improvements in the 
serological phenotype associated with autoimmunity, the levels of autoantibody and BAFF 
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remained elevated compared to B6 mice. This is consistent with the idea that other receptors 
display self-antigens on lymphocytes, and the findings that loss of FcγRI alone does not 
ablate the accumulation of IgG-ICs on myeloid cells. Despite the multiple ways IgG-ICs 
accumulate on myeloid cells, the data show that FcγRI plays a significant role in the disease 
of MRL/lpr mice coincident with defects that lead to accumulation of IgG-ICs and chronic 
FcγR activation.
FcγRI−/−MRL/lpr mice fail to develop nephritis
To assess whether FcγRI is important in lupus nephritis, we quantitated the numbers of renal 
hematopoietic cells and assessed renal pathology in FcγRI−/−MRL/lpr mice. We found that 
compared to MRL/lpr mice, the number of T cells were reduced 6-fold, DCs 2-fold and MFs 
4-fold. Interestingly, the number of B cells that infiltrated the kidney was less than B6 
controls making the reduction 89-fold (Figure 4J). This indicates that migration of DC, MF, 
T and B cells to the kidney is dependent on FcγRI. In addition, the kidneys showed 
significantly reduced glomerular inflammation (Figure 4K) and urine protein levels (Figure 
4L), although levels remained higher than B6 controls, consistent with a partial role of 
FcγRI in kidney disease.
FcγRI−/−MRL/lpr mice failed to develop lupus nephritis coincident with significantly 
reduced serological phenotype. This could reflect reduced autoantibody production that 
diminishes the formation of IgG-ICs, hence the accumulation on the cell surface and 
heightened signal transduction. Alternatively, lupus nephritis might develop independent of 
FcγRI. To sort out these possibilities, we passively transferred pathogenic anti-nucleosome 
IgG2a (PL2-3) into FcγRI−/−MRL/lpr mice. We found that 5-weeks of PL2-3 injection did 
not change the levels of Sm and IgG on the surface of DCs and MFs, or induce glomerular 
inflammation or proteinuria in FcγRI−/−MRL/lpr mice compared to PBS treated control 
mice (Supplemental Figure 2A–E). However, deposits of IgG and C3 remain evident in the 
kidney of MRL/lpr mice regardless of disease pathology or the presence of FcγRI 
(Supplemental Figure 2F). Collectively, the data show that FcγRI plays a major role in many 
of the serological and cellular phenotypes associated with autoimmunity (Figure 4A–I). It 
also partially contributes to kidney disease (Figure 4J–L). This suggests that FcγRIV may 
also play a role in kidney pathology (41). We are currently backcrossing FcγRIV−/− mice to 
the MRL/lpr background to assess this possibility.
Passive transfer of IgG heightens surface ICs coincident with early autoantibody secretion
Our results show that loss of FcγRI markedly reduces the accumulation of IgG-ICs on 
myeloid cells and the pathologies associated with SLE (Figure 4). To begin to understand 
their role in disease, we defined the temporal order of events leading to lupus-related 
pathologies. For this, we developed an in vivo model where we passively transferred 
pathogenic anti-nucleosome IgG2a into IgG-deficient MRL/lpr mice. Our selection of anti-
nucleosome IgG2a (PL2-3) was based on in vitro experiments showing that co-culturing 
PL2-3, but not anti-TNP (Hy1.2; IgG2a), during the derivation of MRL/lpr bone marrow-
derived DCs promoted the accumulation of IgG and secretion of BAFF (Supplemental 
Figure 1F and G). BMDCs from B6 mice treated with PL2-3 failed to secrete BAFF or 
increase the level of surface IgG supporting the findings that accumulation is unique to mice 
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genetically-prone to lupus (Figure 3B–D). In addition, anti-nucleosome (PL2-3) is 
pathogenic, and the IgG2a isotype binds to FcγRI and FcγRIV and is a highly displayed 
isotype on the surface of myeloid cells from MRL/lpr mice (Supplemental Figure 1C).
Our model uses AID−/−MRL/lpr mice since deficiency in activation-induced cytidine 
deaminase (AID) prevents class switch. These mice also fail to develop serological 
phenotypes of autoimmunity or lupus nephritis (34). Thus, passive transfer of anti-
nucleosome IgG2a (PL2-3) would induce disease pathology and allow us to order the events 
that occur during the onset of autoimmune disease. AID−/−MRL/lpr mice were intravenously 
treated with PL2-3 weekly for 2 or 5 weeks (Figure 5A). Separate cohorts were treated with 
PBS, isotype control antibody, or F(ab′)2 of PL2-3. We found that after 2 weeks of PL2-3 
treatment, the levels of surface IgG increased 2-fold on DCs and MFs and showed a punctate 
staining similar to that found on MRL/lpr mice (Figure 5B and 3C). By 5 weeks, the levels 
of IgG on DCs increase to 3-fold, while on MFs the levels remained comparable to those at 
2 weeks. Surface accumulation of IgG was not evident when PL2-3 was injected into B6 
mice (Supplemental Figure 2B), or when AID−/−MRL/lpr mice were treated with F(ab′)2 of 
PL2-3, or an isotype control antibody (anti-TNP; Hy1.2; IgG2a) (Figure 5B). To assess 
whether the treatment of PL2-3 prolonged or enhanced signaling from FcγRs, we quantitated 
the levels of pSyk in ex vivo DCs and MFs (Figure 5C). After 5 weeks of PL2-3 treatment, 
pSyk levels in DCs were increased 1.8-fold, and in MFs the levels were increased 1.5-fold 
compared to PBS treated mice. This suggests that PL2-3 treatment promotes the surface 
accumulation of IgG-ICs, and activates FcγRs on myeloid cells.
To define whether the accumulation of IgG-ICs was associated with autoantibody titers in 
PL2-3 treated AID−/−MRL/lpr mice, we enumerated B cells and measured serum 
autoantibody levels after 2 and 5 weeks of PL2-3 treatment. We found that by 2 weeks, there 
was a 1.5-fold increase in the number of splenic B cells that reached 3.6-fold after 5-weeks 
of injection (Figure 5D). The numbers of DCs, MFs, and T cells were not different at 2 or 5 
weeks post injection (data not shown). Initially, the expanded B cells secreted low levels of 
anti-dsDNA IgM (2 weeks); however, by 5 weeks of treatment, the levels of anti-nucleosome 
and anti-dsDNA IgM were increased 6- and 7-fold respectively (Figure 5E, F). Since the 
levels of total IgM were not affected (Figure 5G), the data suggest that the increase in 
autoantibody titers and the number of B cells was due to activation and expansion of 
autoreactive B cells. Thus, accumulation of IgG-ICs on the surface of myeloid cells is 
concurrent with B cell expansion and the initial production of autoantibody.
Heightened levels of BAFF allow autoreactive B cells to survive during the transitional stage 
of development (42). To determine whether accumulation of IgG-ICs promotes BAFF 
secretion in vivo, we enumerated BAFF secreting MFs and DCs in AID−/−MRL/lpr mice 
after 2 and 5 weeks of PL2-3 injection (Figure 5H). We found that production of BAFF in 
MRL/lpr MFs reached a maximal 11-fold increase at 2 weeks, the time point correlated with 
the maximal accumulation of IgG-ICs on MFs (Figure 5B), then declined to 4-fold over PBS 
or F(ab′)2 controls. In contrast, BAFF secretion in DCs increased 4-fold at 2 weeks and an 
additional 10-fold by 5 weeks post PL2-3 injection. Thus, surface IgG-ICs accumulate 
rapidly on MFs concurrent with early BAFF secretion, but preceding the significant 
increases in the number of B cells and the levels of autoantibodies. In contrast, the 
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accumulation of IgG-ICs on DCs and their secretion of BAFF are delayed, occurring 
concomitantly with B cell expansion and heightened autoantibody.
Passive transfer of anti-nucleosome IgG promotes renal disease
Renal failure is one of the leading causes of mortality in human and murine SLE. To 
understand whether the accumulation of IgG-ICs on the surface of cells precedes lupus 
nephritis, we assessed renal pathology after 2 and 5 weeks of PL2-3 treatment. At 2 weeks, 
H&E stained kidney sections from PL2-3 treated mice did not show morphologic changes 
despite the accumulation of IgG on DCs and MFs (data not shown, Figure 5B). After 5 
weeks of PL2-3 treatment, extensive tubular and glomerular inflammation, including the 
formation of fibrocellular crescents was evident (Figure 5I). These changes were much like 
those found in MRL/lpr mice. In accordance, scores for glomerular and tubulointerstitial 
inflammation, and proteinuria were increased in MRL/lpr mice and in PL2-3 treated 
AID−/−MRL/lpr mice, but not in B6, PBS or F(ab′)2 treated AID−/−MRL/lpr mice (Figure 
5J-L). The ability of PL2-3 to induce kidney pathology was specific to lupus-prone mice, as 
B6 mice treated with PL2-3 did not develop renal pathology (Supplemental Figure 2C–F). 
Our data in the passive antibody transfer model shows that the accumulation of IgG-ICs on 
the cell surface precedes glomerulonephritis. This is much like the timeline of the 
accumulation of surface IgG in MRL/lpr mice where IgG-ICs increase at 10 weeks of age 
prior to high levels of proteinuria (score >2) (Figure 3B, Supplemental Figure 1B). 
Collectively, our data show that passive transfer of anti-nucleosome IgG into 
AID−/−MRL/lpr mice induces the surface accumulation of IgG-ICs on myeloid cells as the 
early antibody response begins, promoting chronic FcγRI signaling and BAFF secretion that 
leads to extensive B cell expansion and lupus nephritis.
Discussion
Our findings identify a previously unidentified defect that promotes the accumulation of 
nuclear antigens (Sm, DNA, and nucleosomes) on the surface of hematopoietic cells. This 
defect was evident in two genetically unrelated strains of lupus-prone mice, and on 
peripheral blood mononuclear cells from SLE patients. On myeloid cells, the self-antigens 
were part of IgG-ICs bound by the activating receptors FcγRI and FcγRIV. B and T cells 
also accumulated self-antigens; however, the receptors involved remain unknown. We used 
several mouse models to define whether accumulation of IgG-ICs on the surface of myeloid 
cells contributes to the pathogenesis of SLE. In the AID−/−MRL/lpr model treated with anti-
nucleosome, we showed that IgG-ICs accumulated concomitantly with the activation of Syk 
and secretion of BAFF, but prior to the significant expansion of autoreactive B cells and 
lupus nephritis. F(ab′)2 of anti-nucleosome IgG did not elicit changes in the serological 
phenotype or renal disease, indicating that the autoimmune phenotype required IgG-ICs/
FcγR interactions. In SLE patients experiencing active disease (SLEDAI >6), nuclear self-
antigens were displayed on the surface of peripheral blood B cells, and to a lesser extent on 
T cells and monocytes. In addition, loss of FcγRI (FcγRI −/−MRL/lpr) reduced surface IgG, 
decreased signal transduction (pSyk, pAkt, and pS6), diminished serum BAFF, and reduced 
kidney disease. Together, the data show that after the early autoantibody response, chronic 
interaction of IgG-ICs and activating FcγRs amplifies the disease process. It also provides 
Kang et al. Page 11













insight into how FcγRs on circulating myeloid cells, rather than kidney mesangial cells, 
might contribute to renal pathology in SLE (26, 43).
Autoreactive B cells are normally maintained in an unresponsive state as a result of chronic 
engagement of the B cell receptor by self-antigens (44). The findings that membrane-bound 
apoptotic self-antigens are present at low levels on the surface of DCs, MFs and B cells from 
B6 mice (Figure 1A) raises the possibility that they deliver tolerogenic signals to B cells 
(45). This is supported by previous studies in the hen egg lysosome (HEL) model of 
tolerance, showing that membrane-bound HEL induces a stronger BCR signal than soluble 
HEL (45), and in the Sm model of tolerance, showing that soluble Sm or snRNPs fail to 
maintain the unresponsive state associated with anergy (46). Thus, in non-autoimmune mice, 
the low levels of nuclear self-antigens on DCs, MFs, and B cells may tolerize low-affinity 
autoreactive B cells. However, when a high burden of nuclear antigens accumulate on 
hematopoietic cells in MLR/lpr mice, they could promote a break in tolerance (44) by 
providing a source of TLR agonists that chronically stimulate TLR7 and TLR9 (47), or by 
providing a source of membrane-bound nuclear antigens that activate autoreactive BCRs “in 
trans”. Similarly, accumulated IgG-ICs on myeloid cells constitutively crosslink activating 
FcγRs and heighten cytokine secretion (Figures 3A–G, 4B–F, 5B, 5C, and 5H, and 
Supplemental Figure 1F–G).
Our data show that hematopoietic cells from both B6 and MRL/lpr mice display nuclear 
self-antigens; however, only MRL/lpr mice develop disease. The low levels of self-antigens 
displayed on B6 hematopoietic cells, and their lack of autoimmune disease, suggest the need 
for a threshold level of activation to promote the autoimmune pathology. Another possibility 
is that a protective signal is conferred by opsonins other than IgG that coat apoptotic debris 
(48). We found that B6 cells displayed low levels of Sm; however, IgG was barely detectable 
(Figure 1A, 1E, 1F, 3B, 3C, and 3D). Similarly, disease-free MRL/MpJ, or 3–9 weeks old 
MRL/lpr mice showed high levels of surface bound nuclear antigens despite low levels of 
surface IgG (Figure 1E, 1F and 3B). This might reflect the binding of C-reactive protein 
(CRP), an acute phase protein that opsonizes apoptotic debris and binds to activating FcγRI 
and inhibitory FcγRIIB (49). Whether or how the exchange of CRP for IgG could promote 
disease remains unclear; however, CRP might confer unique downstream signals that are 
protective (50) since CRPTg(NZB/NZW)F1 mice and CRP-treated MRL/lpr mice show 
delayed disease (51, 52). Although CRP bound apoptotic debris may be protective in a non-
autoimmune-prone environment, in MRL/lpr mice the high burden of apoptotic debris could 
activate intracellular TLRs, triggering a break in tolerance and the production of autoreactive 
antibodies at early ages. This would increase the production of IgG-ICs, thus amplifying the 
downstream effects of FcγRI. It is also supported by the data in Figure 4B-C showing that in 
FcγRI−/−MRL/lpr mice, the levels of Sm were moderately decreased (30–40%), while the 
decrease in IgG were more significant (50–60%) and coincident with the lack of disease 
pathology. The data are consistent with the idea that binding of pathogenic IgG to FcγRI 
gives rise to lupus pathology.
It was striking that AID−/−MRL/lpr mice passively administered pathogenic IgG2a 
developed fulminant lupus nephritis, while AID−/−MRL/lpr mice treated with F(ab′)2 of 
IgG2a or FcγRI−/−MRL/lpr mice treated or untreated with intact IgG2a were void of severe 
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renal disease. The lack of severe disease in the latter mice was observed in spite of the 
presence of renal IgG and C3 deposits (Supplemental Figure 2F). Together, these findings 
indicate that the interaction of IgG-ICs and FcγRI plays crucial roles in the pathogenesis of 
lupus nephritis, but deposits of IgG/C3 in the kidney appears not to be sufficient to induce 
fulminant disease. It is possible that passive transfer of anti-nucleosome IgG2a into 
AID−/−MRL/lpr mice induces deposits in the kidney independent of FcγRs by forming ICs 
with nuclear antigens that deposit on the glomerular basement membrane (53). However, 
since resident renal cells such as mesangial cells, podocytes, and renal endothelial cells do 
not express FcγRI (43), our data showed that lupus nephritis is dependent on constant 
binding of IgG-ICs to FcγRI expressed on hematopoietic cells. Whether disease depends on 
the secretion of FcγR-dependent cytokines, or signals that promote the migration of cells to 
the kidney is under investigation. It is noteworthy that although a previous study showed 
lupus nephritis in MRL/lpr mice lacking the Fc common gamma chain (FcRγc, a subunit of 
murine FcγRI, III, and IV) (54), another study had found that FcRγc -deficient mice 
maintain a partially functional FcγRI (28). Coupled with our data, it raises the possibility 
that FcγRI contributed to disease in the MRL/lpr model.
An interesting observation in autoimmune MRL/lpr mice is that the burden of IgG-ICs 
varies depending on the source of cells. All hematopoietic splenocytes from MRL/lpr mice 
accumulate ICs (Figure 1D–F); however, the levels of surface IgG-ICs on blood monocytes 
(wk30) were comparable to those from B6 mice (Figure 1E). This was also evident in human 
SLE where the levels of surface bound nuclear antigens on circulating monocytes were 
comparable to those from healthy donors (Figure 2A), despite reports that human blood 
monocytes express elevated levels of FcγRI (55). Circulating monocytes activate and 
differentiate into MFs upon migration to tissues. Thus, it is possible that accumulation of 
IgG-ICs on blood monocytes promotes their migration to the tissues leaving only blood 
monocytes that display low levels of nuclear self-antigens. Given that activating FcγRs 
account for 50–60% of the display of nuclear self-antigens on myeloid cells (Figure 3A, 
4C), another possibility is that MFs utilize receptors that are not highly expressed on blood 
monocytes for the display of IgG-opsonized apoptotic debris.
What leads to the accumulation of IgG-ICs on the surface of cells is currently under 
investigation. Possible defects include failure to internalize IgG-ICs bound by FcγRI, 
disrupted trafficking to the lysosome, diminished degradation in the lysosome, or aberrant 
recycling of IgG-ICs (56–58). Our study provides a new insight into how apoptotic debris 
and IgG-ICs contribute to heightened BAFF secretion and lupus nephritis. Recent advances 
in treating lupus show that 43–58% of patients treated with anti-BAFF reduce SLEDAI 
scores more than 4 points compared to 36–46% in control subjects (59). Therefore, 
understanding the molecular events that lead to the accumulation of nuclear self-antigen 
might prove fruitful in providing a means to reduce high BAFF and simultaneously other 
activating FcγR-mediated events that promote autoimmune pathologies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Nuclear self-antigens are displayed on the surface of hematopoietic cells
(A) Splenic DCs, MFs, B cells, T cells, and CD45neg cells from B6 mice were stained with 
anti-Sm (2.12.3, black line) or isotype control antibody (gray line) and analyzed by flow 
cytometry. Representative histograms from >5 experiments (n = >20 mice). (B) Splenic DCs 
or MFs untreated or treated with trypsin and stained for Sm (2.12.3, red). (C) Splenocytes 
untreated or treated with DNase (100 μg/ml) were stained for surface DNA (33H11, red) or 
nucleosome (PL2-3, red). Representative images from 6 experiments (n = 7 mice, 10–15 
cells per mouse). Scale bar = 3.5μm. (D) Splenic DCs, MFs, B cells, T cells, and CD45neg 
cells from MRL/lpr mice (16–28 weeks old) were stained for Sm and analyzed by flow 
cytometry. Representative data from >5 experiments (n = >20 mice). (E) Splenocytes 
(circle) or blood cells (triangle) from B6 (black) or MRL/lpr (white) at different ages were 
stained for Sm and analyzed by flow cytometry. (n = 4–5 mice per age group, 2 
experiments). (F) Surface Sm levels were quantitated on splenocytes from different mouse 
models. (n = 3–14 mice). In (E) results are mean ± SEM. In (F), bars represent median. 
*p<0.05, **p<0.01, ***p<0.001, n.s. = not significant by Mann-Whitney test. MFI = 
Median fluorescence intensity.
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Figure 2. Peripheral blood mononuclear cells from SLE patients accumulate surface nuclear self-
antigens
(A) Whole blood cells from healthy controls (HC) or SLE patients (SLE) with SLEDAI 
score > 6 were analyzed for surface DNA (33H11) or Sm (2.12.3) by flow cytometry. (B) 
Representative histograms are shown for each cell type (isotype antibody: gray, anti-DNA: 
black). n = 8–9 from >3 separate experiments. (C) Peripheral blood T cells from HC (upper 
panels) or SLE patients (lower panels) were stained for CD3 (blue) and DNA (red). Scale 
bar = 3 μm. (n = 3, 10 cells per sample). In (A), bars represent median. *p<0.05, **p<0.01, 
***p<0.001, n.s. = not significant by Mann-Whitney test. MFI = median fluorescence 
intensity.
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Figure 3. Nuclear self-antigens bind FcγRs as IgG-ICs
(A) Surface Sm was stained on splenic DCs and MFs from B6 mice deficient of individual 
FcγR (FcγRI, IIB, III, or IV) or Fc-common-gamma-chain (γ). (n = 4–14 mice, 5 
experiments). (B) Surface IgG levels on splenic DCs and MFs from B6 and MRL/lpr mice at 
different ages were analyzed by flow cytometry. (n = 2–6 mice per age group, 2 
experiments). (C) Purified splenic DCs were stained for surface Sm (magenta) and IgG 
(green). Representative images from >3 experiments. Scale bar = 2.5μm. (n = 5–7 mice, 5–
15 cells per mouse). (D) Colocalization of Sm with IgG on DCs and MFs was analyzed 
using Mander’s Coefficient and ImageJ. Each circle represents a cell (n = 7–15 cells from 2–
3 mice, 4 experiments). Expression levels of phosphorylated (E) Syk, (F) Akt-Threonine308 
(Akt-T), and (G) S6 in splenic DCs and MFs from B6 and MRL/lpr mice were analyzed by 
flow cytometry. (n = 5–15 mice, 2–3 experiments). Levels of FcγRI (H) surface, or (I) gene 
expression, on splenic MFs and DCs from B6, MRL/lpr, and FcγRI−/−MRL/lpr mice were 
analyzed by flow cytometry or qPCR (relative expression over FcγRI−/−MRL/lpr mice, I). (n 
= 3–7 mice, 2 experiments). In (A, B, and D–I) bars represent median. *p<0.05, **p<0.01, 
***p<0.001 by Kruskal-Wallis test (A) or Mann-Whitney test (B and D–I).
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Figure 4. Lack of FcγRI in MRL/lpr mice reduces the levels of surface IgG-IC and lupus-related 
pathologies
(A) Numbers of splenic B cells, T cells, DCs, and MFs from age matched B6, MRL/lpr, or 
FcγRI−/−MRL/lpr mice (20 weeks old) were enumerated by flow cytometry analysis. (n = 5–
7 mice, 2 experiments). (B) Surface Sm levels on splenic DCs, MFs, B cells, and T cells. (C) 
IgG levels on splenic DCs and MFs from B6, MRL/lpr, or FcγRI−/−MRL/lpr mice (>20 
weeks old) were analyzed by flow cytometry. (n = 5–8 mice, 3 experiments). The expression 
of intracellular phosphorylated (D) Syk, (E) Akt-Threonine308, and (F) S6 levels in splenic 
DCs and MFs were analyzed by flow cytometry. The data for B6 and MRL/lpr includes data 
from Figure 3E–G. (n = 5–15, 3 experiments). (G) Anti-nucleosome IgG, (H) anti-dsDNA 
IgG, or (I) BAFF levels in the sera collected from B6, MRL/lpr, or FcγRI−/−MRL/lpr (>20 
weeks old) were measured by ELISA. (n = 4–8 mice from 2 experiments for G and H, n=6–
15 mice from 5 experiments for I). (J) Number of B cells, T cells, DCs, and MFs infiltrating 
the kidneys were enumerated by flow cytometry. (n = 5–11 mice, 2 experiments). (K) Levels 
of glomerular inflammation were scored using H&E stained kidney sections. (n = 5–6, 2 
experiments). (L) Urine samples were analyzed for protein levels. Bars represent median. 
*p<0.05, **p<0.01, ***p<0.001, n.s. = not significant, by Mann-Whitney test (A and D–L) 
or by Kruskal-Wallis test (B, C).
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Figure 5. Anti-nucleosome IgG induces accumulation of IgG-ICs prior to appearance of lupus-
related pathologies
(A) AID−/−MRL/lpr mice were treated (i.v.) with PL2-3 (500 μg/mouse) or control 
antibodies once a week for 2 or 5 weeks. Untreated, age matched B6 and MRL/lpr mice 
were used as controls. (B) Surface bound IgG (green) on purified splenic MFs from PBS 
(upper left) or PL2-3 (lower left) treated mice for 2 weeks. Representative images from 3 
experiments (10–15 cells/mouse). Surface IgG on splenic DCs (upper right) and MFs (lower 
right) analyzed by flow cytometry. (C) The expression of intracellular phosphorylated Syk 
(pSyk) levels in splenic DCs and MFs analyzed by flow cytometry. The data for B6 and 
MRL/lpr control mice includes data from Figure 3E. (D) Splenic B cells enumerated by flow 
cytometry. (E) Levels of anti-nucleosome, (F) anti-dsDNA, or (G) total IgM in sera were 
analyzed by ELISA. (H) BAFF secreting splenic DCs or MFs enumerated by ELISPOT. (I) 
H&E stained kidney sections. Arrows indicate fibrocellular crescents. Representative images 
from >3 experiments. Scale bar = 1μm. Scores of (J) glomerular and (K) tubulointerstital 
inflammation of the kidneys. (L) Proteinuria scores. In (B–L), n = 2–5 mice per treatment 
per experiment, >3 experiments. In (B–H, J–L) bars represent median. *p<0.05, **p<0.01, 
***p<0.001, n.s.= not significant by Kruskal-Wallis test (B) or Mann-Whitney test (C–H, 
and J–L).
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